Cargando…

Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents

Detalles Bibliográficos
Autores principales:	Ayaz, Sameer, Crea, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491010/ https://www.ncbi.nlm.nih.gov/pubmed/32495654 http://dx.doi.org/10.2217/epi-2020-0154

Ejemplares similares

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
por: Esposito, Francesca, et al.
Publicado: (2023)

Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide
por: Stefano, George B., et al.
Publicado: (2020)

Targeting of polycombs to DNA in EMT
por: Battistelli, Cecilia, et al.
Publicado: (2017)

How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2
por: Mehdizadeh, Ali Reza, et al.
Publicado: (2021)

Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties
por: Rosenbloom, Daniel Scholes, et al.
Publicado: (2020)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Synthesis of Potential Antiviral Agents for SARS-CoV-2 Using Molecular Hybridization Approach
por: Wyman, Kailey A., et al.
Publicado: (2022)

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target
por: Qin, Bo, et al.
Publicado: (2023)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection
por: Krishna, Gayathri, et al.
Publicado: (2020)

The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
por: Jans, David A., et al.
Publicado: (2021)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

SARS-CoV-2 cell entry and targeted antiviral development
por: Chen, Zinuo, et al.
Publicado: (2021)

Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
por: Wang, Yi, et al.
Publicado: (2021)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Eosinophils in antiviral immunity and (perhaps) a benefit of having asthma during the SARS-CoV2 pandemic
por: Eid, Ryan, et al.
Publicado: (2021)

SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
por: Rebeaud, Mathieu E., et al.
Publicado: (2020)

Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2
por: Sarkar, Prasanta Kumar, et al.
Publicado: (2021)

In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2
por: Jain, Anisha S., et al.
Publicado: (2021)

Atomistic insight into 2D COFs as antiviral agents against SARS-CoV-2
por: Jahromi, Ahmad Miri, et al.
Publicado: (2022)

Hypochlorous acid solution is a potent antiviral agent against SARS‐CoV‐2
por: Hatanaka, Noritoshi, et al.
Publicado: (2021)

Computational modeling of the pharmacological actions of some antiviral agents against SARS-CoV-2
por: Adegboyega, Abayomi Emmanuel, et al.
Publicado: (2021)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
por: Parums, Dinah V.
Publicado: (2022)

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
por: Lv, Zongyang, et al.
Publicado: (2022)

Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
por: Johansen-Leete, Jason, et al.
Publicado: (2022)

Potential antiviral peptides targeting the SARS-CoV-2 spike protein
por: Khater, Ibrahim, et al.
Publicado: (2022)

CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2
por: Lagni, Anna, et al.
Publicado: (2023)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

SARS-CoV-2 docet
por: Sarli, Leopoldo
Publicado: (2021)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Virtual screening and molecular dynamics simulation for identification of natural antiviral agents targeting SARS-CoV-2 NSP10
por: Zhao, Huilin, et al.
Publicado: (2022)

Antiviral agents against COVID-19: structure-based design of specific peptidomimetic inhibitors of SARS-CoV-2 main protease
por: Frecer, Vladimir, et al.
Publicado: (2020)

Clinical significance of Polycomb gene expression in brain tumors
por: Crea, Francesco, et al.
Publicado: (2010)

Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses
por: Machado-Vieira, Rodrigo, et al.
Publicado: (2021)

Good reasons for targeting SARS-CoV-2 by engineered extracellular vesicles
por: de Marco, Ario, et al.
Publicado: (2022)

SARS-CoV-2-induced senescence as a potential therapeutic target
por: Denholm, Mary, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q6bk6hqnm2dm9a4kjbmaf7gkio